"Multiple Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Descriptor ID |
D009103
|
| MeSH Number(s) |
C10.114.375.500 C10.314.350.500 C20.111.258.250.500
|
| Concept/Terms |
Multiple Sclerosis- Multiple Sclerosis
- Sclerosis, Multiple
- Sclerosis, Disseminated
- Disseminated Sclerosis
- MS (Multiple Sclerosis)
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis".
This graph shows the total number of publications written about "Multiple Sclerosis" by people in this website by year, and whether "Multiple Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 5 | 0 | 5 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 4 | 1 | 5 |
| 2014 | 6 | 0 | 6 |
| 2015 | 2 | 0 | 2 |
| 2016 | 5 | 0 | 5 |
| 2017 | 129 | 16 | 145 |
| 2018 | 133 | 9 | 142 |
| 2019 | 34 | 1 | 35 |
| 2020 | 44 | 1 | 45 |
| 2021 | 33 | 3 | 36 |
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Sclerosis" by people in Profiles.
-
SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature. Neurol Sci. 2021 Dec; 42(12):4881-4884.
-
COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study. Mult Scler Relat Disord. 2021 Oct; 55:103217.
-
SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action? Mult Scler. 2022 01; 28(1):165-167.
-
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022 Mar; 269(3):1316-1334.
-
Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab. Mult Scler Relat Disord. 2021 Oct; 55:103203.
-
Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. J Neurol Neurosurg Psychiatry. 2021 10; 92(10):1033-1043.
-
GIANA allows computationally-efficient TCR clustering and multi-disease repertoire classification by isometric transformation. Nat Commun. 2021 08 04; 12(1):4699.
-
Multiple sclerosis immunomodulatory therapies tested for effectiveness in COVID-19. Neurol Neurochir Pol. 2021; 55(4):357-368.
-
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2022 01; 93(1):24-31.
-
Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. Eur J Neurol. 2021 11; 28(11):3742-3748.